Question-and-Answer Session
Operator
(Operator Instructions) Our first question comes from the line of Dave Turkaly - SIG.
Dave Turkaly - SIG
I know you mentioned in the quarter that you did expand the salesforce. Can you tell us how many people you have now and where that stands versus your goal for the year?
Marty Stephens
In the US, we have about 85 people in the field.
Fred Lampropoulos
In Europe?
Marty Stephens
We have about 25.
Fred Lampropoulos
This is including managers, so about 110, and in the Alveolus salesforce we have 16. So one of the things that we did David as we had thought initially that we might hire a couple of these folks and spread of them over quarters and then as we looked at the training and the time engaging them, we moved them and compressed them a little, particularly on the Endotech division. We talked about maybe 2 in the second, 2 in the third, and 2 in the fourth, and we compressed those because we thought we’d be more effective in training and getting those products out there. So those are the numbers on the salesforce, and we’re pretty well done for the year. There may be a few more, but we’re pretty well wrapped up for the year in terms of those expenses.
Dave Turkaly - SIG
On the charge that was in the SG&A in the quarter, can you tell us how much that was? Typically I would exclude acquisition related charges which would probably mean you beat by instead of $0.02, maybe $0.04.
Kent Stanger
For the quarter, the SG&A involved with our acquisition was $1.9 million.
Dave Turkaly - SIG
That’s the incremental now. Wasn’t there a writeoff in there as well?
Fred Lampropoulos
No. The expenses were incurred in the period. There were no writeoffs. The expense for the six months is about $0.04 and about $0.02 for the quarter.
Kent Stanger
That’s the net. I think he was asking for SG&A increase, and that was about $1.9 million, and there was R&D for another $340,000 and then we had contribution from sales net of cost and you end up with the $0.02 variance.
Dave Turkaly - SIG
You mentioned some of the products that were strong, but standalone division was up a lot. Would you say that the products you highlighted before would be the main drivers of why that was strong this quarter?
- To read the full transcript on Seeking Alpha, click here »
